|1.||Haribabu, Bodduluri: 9 articles (08/2011 - 02/2004)|
|2.||Yokomizo, Takehiko: 7 articles (01/2015 - 10/2005)|
|3.||Shimizu, Takao: 6 articles (01/2015 - 10/2005)|
|4.||Adrian, Thomas E: 6 articles (06/2007 - 10/2002)|
|5.||Ding, Xian-Zhong: 6 articles (06/2007 - 10/2002)|
|6.||Kim, Jae-Hong: 4 articles (10/2013 - 03/2010)|
|7.||Jala, Venkatakrishna R: 4 articles (08/2011 - 02/2004)|
|8.||Bell, Richard H: 4 articles (06/2007 - 04/2005)|
|9.||Tong, Wei-Gang: 4 articles (06/2007 - 10/2002)|
|10.||Dakhama, Azzeddine: 3 articles (03/2014 - 07/2005)|
08/01/2013 - "Although the high-affinity LTB4 receptor BLT1 has been shown to exert proinflammatory roles, the role of BLT2 in allergic inflammation has not been clarified. "
03/01/2010 - "Blockade of airway inflammation and hyperresponsiveness by inhibition of BLT2, a low-affinity leukotriene B4 receptor."
07/15/2005 - "To define the role of the LTB4 receptor (BLT1) in the development of airway inflammation and altered airway function. "
09/13/1996 - "This compound displays high affinity for the human neutrophil LTB4 receptor (Ki = 0.78 nM), blocks LTB4-induced Ca2+ mobilization with an IC50 of 6.6 +/- 1.5 nM, and demonstrates potent oral and topical antiinflammatory activity in a murine model of dermal inflammation."
08/01/1987 - "These data suggest that LTB4 receptor antagonism may contribute to inhibition of inflammation by NDGA."
|2.||Asthma (Bronchial Asthma)
01/01/2012 - "The aim of this study was to characterise the genes for the two pivotal LTB4 receptors, LTB4R1 and LTB4R2 in lung tissue and determine if polymorphisms spanning these genes are associated with asthma and disease severity. "
01/01/2012 - "Leukotriene B4 receptor locus gene characterisation and association studies in asthma."
10/01/2005 - "Based on the finding that leukotriene B4 receptor 1 (BLT1) is expressed highly in Th2 lymphocytes, we analyzed the roles of BLT1 using an OVA-induced bronchial asthma model. "
06/01/2010 - "Theses studies show differential effects of LTB4 receptor antagonism on neutrophil responses in vivo and suggest RO5101576 may represent a potential new treatment for pulmonary neutrophilia in asthma."
03/01/2014 - "Numbers of CD8(+) T cells expressing the leukotriene B4 (LTB4) receptor, BLT1, have been correlated with asthma severity. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
09/30/2005 - "LTB4 receptor antagonists block growth and induce apoptosis in pancreatic cancer cells both in vitro and in vivo. "
10/01/2002 - "LTB4 receptor blockade and inhibition of the downstream signal pathway are likely to be valuable for the treatment of human pancreatic cancer."
10/01/2002 - "Both LTB4 receptor types were found to be expressed in human pancreatic cancer cells. "
06/01/2007 - "We have previously shown that the leukotriene B4 receptor antagonist, LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells both in vitro and in vivo. "
06/01/2007 - "Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells."
02/01/1999 - "The LTB4 receptor antagonist ONO-4057 may thus be beneficial in the treatment of crescentic glomerulonephritis."
02/01/1999 - "To evaluate the role of leukotriene B4 (LTB4) in glomerulonephritis, this study was conducted to examine whether ONO-4057, an LTB4 receptor antagonist, moderated nephritis caused by the injection of nephrotoxic serum (NTS) into Wistar-Kyoto rats. "
|5.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
11/01/1990 - "We evaluated the efficacy of 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)-3,4-dihydro-8-propyl -2H-1-benzopyran-2-carboxylic acid (SC-41930), a potent, orally active leukotriene B4 receptor antagonist, in a model of inflammatory bowel disease. "
06/01/1993 - "These potent, LTB4 receptor antagonists may well have application in the medical management of disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease, contact dermatitis, and psoriasis, where LTB4 is implicated as an inflammatory mediator."
04/01/1995 - "SC-41930 (7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxyl]-3,4-dihy dro-8-propyl-2H - 1-benzopyran-2-carboxylic acid), a first-generation LTB4 receptor antagonist, inhibited the chemotactic actions of LTB4 when given orally with an ED50 value of 1.7 mg/kg. The second-generation LTB4 receptor antagonist, SC-53228 [(+)-(S)-7-(3-(2-(cyclopropylmethyl)-3-methoxy-4- [(methylamino)carbonyl]phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1- benzopyran-2-propanoic acid], inhibited LTB4-induced chemotaxis when given intragastrically with an ED50 value of 0.07 mg/kg. Furthermore, SC-53228 inhibited 12(R)-HETE-induced granulocyte chemotaxis with an oral ED50 value of 5.8 mg/kg. When dosed orally over a range of 0.03-100 mg/kg, SC-53228 gave Cmax plasma concentrations of 0.015-41.1 micrograms/ml. SC-53228 inhibited LTB4-primed membrane depolarization of human neutrophils with an IC50 value of 34 nM. As a potent LTB4 receptor antagonist, SC-53228 may well have application in the medical management of disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease, contact dermatitis, and psoriasis, in which LTB4 and/or 12(R)-HETE are implicated as inflammatory mediators."
|2.||LY 293111 (LY293111)
|5.||4- (3- (6- (3- benzo(1,3)dioxol- 5- yl- 5- thiophen- 3- ylphenoxy)hexyl)- 2- (2- carboxyethyl)phenoxy)butyric acid
|6.||7- (3- (2- (cyclopropylmethyl)- 3- methoxy- 4- ((methylamino)carbonyl)phenoxy)propoxy)- 3,4- dihydro- 8- propyl- 2H- 1- benzopyran- 2- propanoic acid
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Prostatectomy (Retropubic Prostatectomy)